Visszavonva2. fázis
Utilization of Hepatitis B Virus NAT+ Donors for Hepatitis B Vaccinated Lung Transplant Candidates
A legfontosabb adatok
- Ki végzi
- University of Pennsylvania
- Hol
- Philadelphia (Egyesült Államok)A helyszín megnézése
- Azonosító
- Állapot
- Visszavonva
- Fázis
- 2. fázis
- Kezdés
- 2022. szept. 6.
- Befejezés
- 2024. aug. 1.
- A vizsgálat típusa
- Beavatkozással járó
- A vizsgált kezelések
- Hepatitis B Immune Globulin and entecavir, tenofovir disoproxil, or tenofovir alafenamide
- A regiszteradat frissítve
- 2024. augusztus 6.
- Miért állt le
- Insufficient enrollment; departure of primary investigator from institution
Ki vehet részt
- Életkor
- 18 év – 70 év
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 8 feltétel megnézéseKevesebb
Ki vehet részt
- Age 18-70 years
- Able to provide informed consent
- Willing and able to travel to the University of Pennsylvania for routine post-transplant study visits
- Pre-menopausal women must agree to use birth control in accordance with the Mycophenolate Risk Evaluation and Mitigation Strategy (REMS) following transplant
- Both men and women must agree to use at least one barrier method of birth control or remain abstinent following transplant due to risk of HBV transmission
- Appropriate HBV vaccine pre-transplant response, defined as HBV sAb ≥12.00 mIU/mL
Ki nem vehet részt
- Transplant candidate characteristics:; Age >70 years; Any chronic liver disease (excluding non-alcoholic fatty liver disease (NAFLD)) associated with persistently elevated liver enzymes; Significant fibrosis (≥F2 on Fibroscan or Fib4 ≥1.67 (for patients unable to complete Fibroscan and without liver disease risk factors)); Inadequate insurance coverage of entecavir, tenofovir disoproxil, or tenofovir alafenamide; Retransplant candidate; Current use of extracorporeal membrane oxygenation (ECMO) or mechanical ventilation as a bridge to lung transplantation; HIV infection; Chronic kidney disease with estimated glomerular filtrate rate less than 50 ml/min/1.73 m2; Small bowel dysmotility or plan for prolonged medications and/or nutrition via tube route in the post-transplant period; Significant human leukocyte antibody (HLA) sensitization (Calculated Panel Reactive Antibody (CPRA) ≥60%); Planned or high likelihood of anti-thymocyte globulin induction immunosuppression or rituximab treatment; Known hypercoagulable states including positive antiphospholipid antibodies with prior venous or arterial thromboembolic events or Factor V Leiden or Prothrombin mutations with or without prior venous or arterial thromboembolic events; History of hypersensitivity or anaphylactic reaction to immune globulin or similar products; Receiving or anticipated to receive drugs with significant entecavir or tenofovir interactions including phenytoin/fosphenytoin, oxcarbazepine, phenobarbital, primidone, rifabutin, and rifampin
- Donor characteristics:; Donation after circulatory death donor; Hepatitis C Virus (HCV) NAT+; PaO2/FiO2 <300 on FiO2 = 100% and PEEP=5; Age >55 years; Smoking history >20 pack years
Helyszínek itt: Egyesült Államok
- Hospital of University of PennsylvaniaPhiladelphia, Egyesült Államok
A vizsgálatról
Mit akar kideríteni a vizsgálat
The objective of this study is to determine the safety and efficacy of transplanting lungs from hepatitis B virus (HBV) nucleic acid test positive (NAT+) donors into HBV vaccinated HBV surface antibody positive (sAb+) lung transplant candidates, who will then be treated with Hepatitis B Immune Globulin (HBIG) and entecavir, tenofovir disoproxil, or tenofovir alafenamide.
A vizsgálat csoportja
- Recipient of Hepatitis B NAT+ DonorEgyéb csoport
All subjects will then be treated with Hepatitis B Immune Globulin and entecavir, tenofovir disoproxil, or tenofovir alafenamide (choice of specific drug to be based on long-term cost, clinical response, and renal function)
Kezelés: Hepatitis B Immune Globulin and entecavir, tenofovir disoproxil, or tenofovir alafenamide
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Utilization of Hepatitis B Virus Nucleic Acid Test Positive Donors for Hepatitis B Vaccinated Lung Transplant Candidates
- A regiszteradat frissítve
- 2024. augusztus 6.